NBIO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 23:03):

Stats
今日成交量	1 700.00
平均成交量	63 766.00
市值	16.96M
EPS	$0 ( 2024-02-14 )
下一个收益日期	( $0 ) 2024-06-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.99
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Holden Lowell Thomas	Buy	112 500	Common Stock
2024-03-31	Carrick Sean	Buy	225 000	Common Stock
2024-03-31	Karas Douglas John	Buy	27 100	Common Stock
2023-12-29	Carrick Sean	Buy	239 300	Common Stock
2023-12-29	Holden Lowell Thomas	Buy	119 650	Common Stock

INSIDER POWER
58.65
Last 100 transactions
Buy: 40 920 261 \| Sell: 7 165 000

Nascent Biotech, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nascent Biotech, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.0236

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.0236

FY	2022
营收:	$1.00M
毛利润:	$1.00M (100.00 %)
EPS:	$-0.00140

FY	2021
营收:	$750 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

Nascent Biotech, Inc.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.